344 results on '"Losonczy, G."'
Search Results
2. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
3. 1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
4. Nivolumab-Induced Ulcerative Keratitis-A Case Report
5. Durvalumab+ Tremelimumab + Platin-Etoposide in first-line extensive-stage SCLC (ES-SCLC): 36-month Overall Survival from the Phase 3 CASPIAN study
6. Low prevalence of spectacle use in the Hungarian Roma population indicates unmet health needs
7. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
8. LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
9. Detection of factor XIII-A is a valuable tool for distinguishing dendritic cells and tissue macrophages in granuloma annulare and necrobiosis lipoidica
10. Clinical relevance is associated with allergen-specific wheal size in skin prick testing
11. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
12. 103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
13. P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
14. OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
15. Exhaled breath condensate pH
16. Exhaled breath condensate: adenosine, ATP and other purines
17. Increased citrullination in lung cancer does not lead to the production of anti-citrullinated protein antibodies: 314
18. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
19. Growth factors in pulmonary arterial hypertension: Focus on preserving right ventricular function
20. CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)
21. Primary pulmonary lymphoma with an initial suspicion of a neuroendocrine tumor: V696
22. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
23. 40%ige Glukose-Augentropfen gegen Hornhautödeme: Eine seltene Nebenwirkung
24. Lipopolysaccharide exposure makes allergic airway inflammation and hyper-responsiveness less responsive to dexamethasone and inhibition of iNOS
25. Gestational resistance to the pulmonary vasoconstrictor effect of the TxA2 mimetic U-46619: possible mechanism
26. Increased interferon-γ- and interleukin-4-synthesizing subsets of circulating T lymphocytes in pregnant asthmatics
27. GENOMIC INVESTIGATION OF ASTHMA IN HUMAN AND ANIMAL MODELS
28. Post-partum prolongation of the atrial repolarization in rabbit
29. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
30. PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
31. PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC
32. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
33. Diagnostic Value of Peripheral and Bronchoalveolar Leukocyte Profile in Lung Transplant Recipients After Alemtuzumab Induction Therapy. A Single Center Experience
34. MA 10.05 Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial
35. Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
36. Proteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab
37. LBA89 - PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
38. Clinical relevance is associated with allergen-specific wheal size in skin prick testing
39. Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
40. Relationship of Circulating C5a and Complement Factor H Levels With Disease Control in Pregnant Women With Asthma
41. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial
42. (1172) - Diagnostic Value of Peripheral and Bronchoalveolar Leukocyte Profile in Lung Transplant Recipients After Alemtuzumab Induction Therapy. A Single Center Experience
43. Adaptive induction of NF-E2–Related Factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia
44. TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results
45. 1364P - Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
46. Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study
47. Changes in Exhaled Breath Condensate pH in Healthy and Asthmatic Pregnant Women
48. PCN221 - The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours
49. 30P - Proteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab
50. Detection of factor XIII‐A is a valuable tool for distinguishing dendritic cells and tissue macrophages in granuloma annulare and necrobiosis lipoidica
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.